[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editor's Correspondence
July 9, 2001

Quinolones for Community-Acquired Pneumonia

Arch Intern Med. 2001;161(13):1681-1682. doi:

The article by the Drug-Resistant Streptococcus pneumoniae (DRSP) Therapeutic Working Group1 on the management of community-acquired pneumonia (CAP) has generated great interest. This week I received a brochure promoting azithromycin with a copy of the DRSP Therapeutic Working Group article enclosed. The brochure introduced the article as follows: "The Centers for Disease Control (CDC) Therapeutic Working Group recommends macrolides as first-line therapy" for CAP. The DRSP Therapeutic Working Group met at the CDC in 1998, but is not identified as a part of the CDC. Does the article constitute official CDC recommendations?

First Page Preview View Large
First page PDF preview
First page PDF preview
×